Is escitalopram a suitable first‑line treatment for a 58‑year‑old man with mild‑to‑moderate depression who wants to avoid sedation and visual side‑effects and has a family history of glaucoma?

Escitalopram for Mild-to-Moderate Depression with Family History of Glaucoma

Escitalopram is an appropriate first-line treatment for this patient, as a family history of glaucoma alone is not a contraindication to its use. 1

Understanding the Glaucoma Risk Context

The critical distinction is between open-angle glaucoma (the chronic, hereditary form) and acute angle-closure glaucoma (the rare medication-induced emergency):

• Family history increases the odds of developing primary open-angle glaucoma (POAG) by 1.92 to 9.2-fold depending on the number of affected relatives, but this relates to chronic open-angle disease, not acute medication-induced angle closure. 2, 1
• Pre-existing glaucoma is almost always open-angle glaucoma because angle-closure glaucoma, when diagnosed, can be treated definitively with iridectomy. 3
• Open-angle glaucoma is not a risk factor for angle-closure glaucoma. 3

Pre-Prescribing Assessment Algorithm

Step 1: Clarify the family history

• Ask specifically whether affected relatives have open-angle or angle-closure glaucoma. 2, 1
• If family members have angle-closure glaucoma, proceed with heightened caution and ophthalmologic evaluation. 1

Step 2: Screen for high-risk anatomic features for angle closure

The following anatomic factors are more predictive of angle-closure risk than family history alone: 1

• Hyperopia (farsightedness), especially in older patients 2, 1
• Narrow angles on gonioscopy 2, 1
• Asian ethnicity (higher prevalence of narrow angles) 2, 1
• Age >40 years (lens thickening increases risk) 2, 1
• Small corneal diameter 1
• Shallow anterior chamber depth 1

Step 3: Determine need for ophthalmologic evaluation

• If the patient has any of the high-risk anatomic features listed above, obtain ophthalmologic evaluation with gonioscopy before starting escitalopram. 1
• If the patient has only a family history of open-angle glaucoma without high-risk anatomic features, escitalopram can be safely prescribed. 2, 1

Why Escitalopram is Suitable for This Patient

Efficacy for mild-to-moderate depression:

• Escitalopram is recommended by the American College of Physicians as a first-line treatment for major depression, with selection based on adverse effect profiles, cost, and patient preferences. 4
• Escitalopram demonstrates superior efficacy compared to placebo and is at least as effective as other SSRIs, SNRIs, and bupropion. 5, 6
• It shows a rapid onset of antidepressant action, often within 1-2 weeks. 3, 6

Favorable side effect profile for this patient's concerns:

• Escitalopram is the most selective SSRI with minimal effects on other receptors, resulting in generally better tolerability compared to other antidepressants. 7, 5, 6
• It has a low propensity for sedation compared to other antidepressants. 6
• Visual side effects are not a prominent feature of escitalopram treatment. 6

Patient Counseling Requirements

Regarding angle-closure glaucoma risk:

• Advise the patient that escitalopram can cause mild pupillary dilation, which in susceptible individuals can lead to an episode of angle-closure glaucoma. 3
• Patients may wish to be examined to determine whether they are susceptible to angle closure and have a prophylactic procedure (e.g., iridectomy) if they are susceptible. 3
• Warn the patient to seek immediate care for sudden eye pain, headache, blurred vision, or halos around lights. 2, 1

Regarding depression treatment:

• Patients should be monitored for emergence of suicidal ideation and behavior, especially during the first 1-2 weeks of treatment and when doses are adjusted. 4, 3
• While patients may notice improvement within 1-4 weeks, they should continue therapy as directed. 3

Monitoring Recommendations

• Baseline IOP measurement and optic disc examination are recommended for patients with any glaucoma risk factors. 2, 1
• Patients with family history should begin comprehensive ophthalmologic screening by age 40. 2, 1
• Assess patient status, therapeutic response, and adverse effects on a regular basis beginning within 1-2 weeks of initiation. 4
• If angle-closure symptoms develop, discontinue escitalopram immediately and refer emergently to ophthalmology. 1

Critical Pitfalls to Avoid

• Approximately 75% of glaucoma cases remain undiagnosed, so family members may have unrecognized disease. 2, 1
• Do not confuse family history of open-angle glaucoma (a chronic hereditary condition) with risk for acute angle-closure glaucoma (a rare medication-induced emergency). 2, 1, 3
• Hyperopia and shallow anterior chambers are more predictive of angle-closure risk than family history alone. 1
• Do not co-administer escitalopram with citalopram, as escitalopram is the active isomer of racemic citalopram. 3